[1] Sahmay S, Aydin Y, Oncul M, Senturk LM. Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms. J Assist Reprod Genet. 2014;31(2):213-20.
[2] Pigny P, Jonard S, Robert Y, Dewailly D. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 2006;91(3):941-5.
[3] Tran ND, Cedars MI, Rosen MP. The role of anti-mullerian hormone (AMH) in assessing ovarian reserve. J Clin Endocrinol Metab. 2011;96(12):3609-14.
[4] Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde E, Broekmans FJ. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. The Journal of Clinical Endocrinology & Metabolism. 2006;91(10):4057-63.
[5] Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update. 2008;14(4):367-78.
[6] Mohammad MB, Seghinsara AM. Polycystic Ovary Syndrome (PCOS), Diagnostic Criteria, and AMH. Asian Pacific journal of cancer prevention: APJCP. 2017;18(1):17.
[7] Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003;88(12):5957-62.
[8] Usta T, Oral E. Is the measurement of anti-Müllerian hormone essential? Current Opinion in Obstetrics and Gynecology. 2012;24(3):151-7.
[9] Vembu R, Reddy NS. Serum AMH Level to Predict the Hyper Response in Women with PCOS and Non-PCOS Undergoing Controlled Ovarian Stimulation in ART. J Hum Reprod Sci. 2017;10(2):91-4.
[10] Murphy M, Hall J, Adams J, Lee H, Welt C. Polycystic ovarian morphology in normal women does not predict the development of polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 2006;91(10):3878-84.
[11] Reinehr T, Kulle A, Rothermel J, Knop C, Lass N, Bosse C, et al. Weight loss in obese girls with polycystic ovarian syndrome is associated with a decrease in Anti-Muellerian Hormone concentrations. Clinical endocrinology. 2017;87(2):185-93.
[12] Moslehi N, Shab-Bidar S, Ramezani FT, Mirmiran P, Azizi F. Is ovarian reserve associated with body mass index and obesity in reproductive aged women? A meta-analysis. Menopause (New York, NY). 2018.
[13] Nilsson-Condori E, Hedenbro JL, Thurin-Kjellberg A, Giwercman A, Friberg B. Impact of diet and bariatric surgery on anti-Mullerian hormone levels. Hum Reprod. 2018;33(4):690-3.
[14] Teede H, Misso M, Costello M, Dokras A, Laven J, Moran L, et al. International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2018. Monash University: Melbourne, Australia. 2018.
[15] Drakopoulos P, Blockeel C, Stoop D, Camus M, de Vos M, Tournaye H, et al. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? Hum Reprod. 2016;31(2):370-6.
[16] Team RDC. A language and environment for statistical computing. http://www R-project org. 2009.
[17] Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12(1):77.
[18] Sachs MC. plotROC: A Tool for Plotting ROC Curves. Journal of Statistical Software. 2017;79(c02).
[19] Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32-5.
[20] Shan G. Improved Confidence Intervals for the Youden Index. PLoS One. 2015;10(7):e0127272.
[21] Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10(2):77-83.
[22] Saxena U, Ramani M, Singh P. Role of AMH as Diagnostic Tool for Polycystic Ovarian Syndrome. Journal of obstetrics and gynaecology of India. 2018;68(2):117-22.
[23] Zhang F, Liu XL, Rong N, Huang XW. Clinical value of serum anti-mullerian hormone and inhibin B in prediction of ovarian response in patients with polycystic ovary syndrome. J Huazhong Univ Sci Technolog Med Sci. 2017;37(1):70-3.
[24] Alviggi C, Conforti A, Caprio F, Gizzo S, Noventa M, Strina I, et al. In Estimated Good Prognosis Patients Could Unexpected "Hyporesponse" to Controlled Ovarian Stimulation be Related to Genetic Polymorphisms of FSH Receptor? Reproductive sciences (Thousand Oaks, Calif). 2016;23(8):1103-8.
[25] Simões-Pereira J, Nunes J, Aguiar A, Sousa S, Rodrigues C, Matias JS, et al. Influence of body mass index in anti-Müllerian hormone levels in 951 non-polycystic ovarian syndrome women followed at a reproductive medicine unit. Endocrine. 2018:1-5.
[26] Kriseman M, Mills C, Kovanci E, Sangi-Haghpeykar H, Gibbons W. Antimullerian hormone levels are inversely associated with body mass index (BMI) in women with polycystic ovary syndrome. J Assist Reprod Genet. 2015;32(9):1313-6.
[27] Lefebvre T, Dumont A, Pigny P, Dewailly D. Effect of obesity and its related metabolic factors on serum anti-Müllerian hormone concentrations in women with and without polycystic ovaries. Reproductive biomedicine online. 2017;35(3):325-30.
[28] Buyuk E, Seifer DB, Illions E, Grazi RV, Lieman H. Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with normal ovarian reserve. Fertility and sterility. 2011;95(7):2364-8.
[29] Panidis D, Farmakiotis D, Rousso D, Katsikis I, Kourtis A, Diamanti-Kandarakis E. Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary syndrome. Fertility and sterility. 2005;84(2):538-40.
[30] Katsikis I, Karkanaki A, Misichronis G, Delkos D, Kandaraki EA, Panidis D. Phenotypic expression, body mass index and insulin resistance in relation to LH levels in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2011;156(2):181-5.
[31] Guedikian AA, Lee AY, Grogan TR, Abbott DH, Largaespada K, Chazenbalk GD, et al. Reproductive and metabolic determinants of granulosa cell dysfunction in normal-weight women with polycystic ovary syndrome. Fertil Steril. 2018;109(3):508-15.
[32] Karkanaki A, Vosnakis C, Panidis D. The clinical significance of anti-Mullerian hormone evaluation in gynecological endocrinology. Hormones (Athens, Greece). 2011;10(2):95-103.